MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

513.96 -5.22

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

504.13

Max

543.35

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+28.89% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1B 12B
Vorige openingsprijs	519.18
Vorige sluitingsprijs	513.96

Nieuwssentiment

By Acuity

34%

66%

113 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 apr 2026, 23:17 UTC

Winsten

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Populaire aandelen

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

Belangrijke Marktbewegers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisities, Fusies, Overnames

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

Belangrijke Marktbewegers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

Belangrijke Marktbewegers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Marktinformatie

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Marktinformatie

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Marktinformatie

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Marktinformatie

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Marktinformatie

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Marktinformatie

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Marktinformatie

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Winsten

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

28.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 28.89%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

113 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.